David Beckwée1,2, Laurence Leysen3,4, Kaipo Meuwis3, Nele Adriaenssens3. 1. Rehabilitation Sciences Research Department, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. david.beckwee@vub.ac.be. 2. Frailty in Ageing Research Department, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. david.beckwee@vub.ac.be. 3. Rehabilitation Sciences Research Department, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. 4. Pain in Motion Research Group, Brussels, Belgium.
Abstract
BACKGROUND: Although aromatase inhibitors have proven to be an effective treatment of hormone receptor-positive breast cancer in postmenopausal women, aromatase inhibitor-induced arthralgia (AIA) is an adverse event associated with low compliance with treatment. The aim of this literature study is to assess the prevalence of AIA and to provide an overview of significant predictors for the development of AIA. METHODS: A systematic review was conducted using PubMed, Cochrane Library and Web of Science. A meta-analysis was performed and heterogeneity has been investigated by moderator analyses. The meta-analysis was repeated with studies that were considered as best evidence, i.e. studies with an above-average score on the STROBE checklist. RESULTS: Twenty-one studies (13,177 participants) were included. Prevalence rates ranged from 0.200 to 0.737. Meta-analysis resulted in a pooled estimate of 0.459 (95% CI = [0.397-0.520) with a high heterogeneity (I 2 = 98%). Moderator analysis showed no differences regarding heterogeneity. Predictors for the development of AIA included a body mass index of 25-30 kg/m2 (OR = 0.33), taxane-based chemotherapy (OR = 4.08), stage III cancer (OR = 0.32) and a duration of menopause of 5-10 years (OR = 1.10) or >10 years (OR = 0.44-3.29) (An OR <1 indicates a predictor of lower risk of AIA). DISCUSSION: Despite the established benefits of AI, an important portion of the patients experiences AIA. More research is needed to investigate the efficacy of treatments such as exercise therapy for AIA.
BACKGROUND: Although aromatase inhibitors have proven to be an effective treatment of hormone receptor-positive breast cancer in postmenopausal women, aromatase inhibitor-induced arthralgia (AIA) is an adverse event associated with low compliance with treatment. The aim of this literature study is to assess the prevalence of AIA and to provide an overview of significant predictors for the development of AIA. METHODS: A systematic review was conducted using PubMed, Cochrane Library and Web of Science. A meta-analysis was performed and heterogeneity has been investigated by moderator analyses. The meta-analysis was repeated with studies that were considered as best evidence, i.e. studies with an above-average score on the STROBE checklist. RESULTS: Twenty-one studies (13,177 participants) were included. Prevalence rates ranged from 0.200 to 0.737. Meta-analysis resulted in a pooled estimate of 0.459 (95% CI = [0.397-0.520) with a high heterogeneity (I 2 = 98%). Moderator analysis showed no differences regarding heterogeneity. Predictors for the development of AIA included a body mass index of 25-30 kg/m2 (OR = 0.33), taxane-based chemotherapy (OR = 4.08), stage III cancer (OR = 0.32) and a duration of menopause of 5-10 years (OR = 1.10) or >10 years (OR = 0.44-3.29) (An OR <1 indicates a predictor of lower risk of AIA). DISCUSSION: Despite the established benefits of AI, an important portion of the patients experiences AIA. More research is needed to investigate the efficacy of treatments such as exercise therapy for AIA.
Entities:
Keywords:
Aromatase inhibitor; Arthralgia; Breast cancer; Prevalence
Authors: Leilani Morales; Steven Pans; Robert Paridaens; Rene Westhovens; Dirk Timmerman; Johan Verhaeghe; Hans Wildiers; Karin Leunen; Frederic Amant; Patrick Berteloot; Ann Smeets; Erik Van Limbergen; Caroline Weltens; Walter Van den Bogaert; Luc De Smet; Ignace Vergote; Marie-Rose Christiaens; Patrick Neven Journal: Breast Cancer Res Treat Date: 2006-10-24 Impact factor: 4.872
Authors: C A DeNysschen; H Burton; F Ademuyiwa; E Levine; S Tetewsky; T O'Connor Journal: Eur J Cancer Care (Engl) Date: 2013-12-02 Impact factor: 2.520
Authors: Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar Journal: Lancet Oncol Date: 2008-08-12 Impact factor: 41.316
Authors: Jo Nijs; Laurence Leysen; Nele Adriaenssens; Maria Encarnación Aguilar Ferrándiz; Nele Devoogdt; An Tassenoy; Kelly Ickmans; Dorien Goubert; C Paul van Wilgen; Amarins J Wijma; Kevin Kuppens; Wouter Hoelen; Astrid Hoelen; Niamh Moloney; Mira Meeus Journal: Acta Oncol Date: 2016-05-04 Impact factor: 4.089
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Laurence Leysen; David Beckwée; Jo Nijs; Roselien Pas; Thomas Bilterys; Sofie Vermeir; Nele Adriaenssens Journal: Support Care Cancer Date: 2017-08-10 Impact factor: 3.603
Authors: Alison T Stopeck; Patricia A Thompson; Jessica A Martinez; Betsy C Wertheim; Denise J Roe; Pavani Chalasani; Jules Cohen; Lea Baer; H-H Sherry Chow Journal: Breast Cancer Res Treat Date: 2022-01-18 Impact factor: 4.872
Authors: Andrew Ernst; Kathryn E Flynn; Elizabeth M Weil; Bradley H Crotty; Sailaja Kamaraju; Nicole Fergestrom; Joan Neuner Journal: Clin Breast Cancer Date: 2020-07-22 Impact factor: 3.225